Biology Methods & Protocols · Nov 14, 2026

Oral Wegovy Super-Responders are Characterized by Greater Pretreatment Weight Gain, Faster Early Dose Escalation, and Larger On-Treatment Blood Pressure Reductions

By Murugadoss K, Venkatakrishnan AJ, Soundararajan V

Early weight-loss responses to oral glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vary substantially, and super-responders are incompletely characterized. Using de-identified electronic health records, we studied 9,287 GLP-1 RA-naive patients prescribed oral Wegovy. Of 8,381 patients with an index weight, 3,011 had a weight between 30 and 180 days and were classified by their best percent weight change as non-responders (no loss), responders (>0–5% loss), strong responders (>5–10%), or super-responders (>10%). Body weight was traced back five years, and HbA1c, blood pressure, comorbidities, dose escalation, and phenotypes extracted from clinical notes using AI-augmented curation were compared across these treatment response groups. Super-responders weighed less at initiation than non-responders (94.1 versus 101.7 kg; P < 0.001) and had weighed 7.6% less five years earlier, against 0.8% less among non-responders (P < 0.001). Among patients of the same starting weight, faster weight gain between five years and six months before treatment predicted lower weight at day 90 (0.11 kg per kg per year; P = 0.015). Super-responders lost 7.2% by day 60 and 11.4% by day 90, returning within two months to their weight from five years earlier. Baseline HbA1c and blood pressure did not differ across groups, and the share of women and of type 2 diabetes varied only modestly with response. Super-responders escalated earlier (37% versus 24% were prescribed >1.5 mg at day 30;P=0.001) and their systolic blood pressure fell more by day 90 (10.2 versus 3.3 mmHg; P = 0.006). Among 1,978 phenotypes AI-curated from unstructured clinical notes, before the first prescription, severe obesity was documented less in super-responders (19.4% versus 36.1%; P < 0.001; q = 0.003). Pre-treatment weight trajectory and dosage emerged as associates of early response, but the outcome-defined groups and short follow-up make these findings hypothesis-generating.

doi.org/10.1093/biomethods/bpag068Interventions

AgingResearch.News